20035-32-9

Usage

Uses

Used in Organic Synthesis:
4-Bromo-3-hydroxybenzaldehyde is used as a key intermediate in the synthesis of various complex organic compounds. Its unique structure, which includes both bromine and aldehyde functional groups, makes it a valuable building block for creating a wide range of molecules with diverse applications.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, 4-Bromo-3-hydroxybenzaldehyde is employed as an intermediate in the production of certain drugs. Its presence in the synthesis process allows for the creation of pharmaceutical compounds with specific therapeutic properties, contributing to the development of new medications and treatments.
Used in Research and Development:
4-Bromo-3-hydroxybenzaldehyde is also utilized in research and development settings, where it serves as a starting material for exploring new chemical reactions and pathways. Its reactivity and functional groups make it an interesting subject for study, potentially leading to the discovery of novel compounds and applications.

Upstream product

• 2737-19-1 4-bromo-3-hydroxy-benzyl alcohol 
• 100-83-4 meta-hydroxybenzaldehyde 
• 108-39-4 3-methyl-phenol 
• 122-46-3 3-acetoxytoluene 
• 106291-80-9 methyl 4-bromo-3-hydroxybenzoate 

Downstream Products

• 43192-34-3 4-bromo-3-methoxybenzaldehyde 
• 540779-39-3 ethyl (E)-4-bromo-3-(3'-tert-butoxycarboxamidopropoxy)cinnamate 
• 540779-43-9 ethyl (E)-4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-(3'-aminopropoxy)cinnamate 
• 736992-51-1 ethyl (E)-3-[5-(adamant-1-yl)-2-(3-(tert-butoxycarbonylamino)propoxy)-4-hydroxy-2-methylbiphenyl-4-yl]acrylate 
• 540779-38-2 ethyl (E)-4-bromo-3-hydroxycinnamate 
• 906673-54-9 4-(4-bromo-3-formaldehydephenoxy)benzonitrile 
• 132041-03-3 5-((2R,4R,5S,6R)-4,5-Dihydroxy-6-methyl-tetrahydro-pyran-2-yl)-4-methoxy-3-phenylsulfanyl-3H-isobenzofuran-1-one 
• 132041-16-8 4-((2S,3R,4S,5R,6R)-4,5-Bis-benzyloxy-3-bromo-6-methyl-tetrahydro-pyran-2-yl)-3-methoxy-benzoic acid benzotriazol-1-yl ester 
• 132041-14-6 4-((2S,3R,4S,5R,6R)-4,5-Bis-benzyloxy-3-bromo-6-methyl-tetrahydro-pyran-2-yl)-N,N-diethyl-3-methoxy-benzamide 
• 132041-00-0 4-((2R,4R,5R,6R)-4,5-Bis-benzyloxy-6-methyl-tetrahydro-pyran-2-yl)-N,N-diethyl-3-methoxy-benzamide 
• 132040-99-4 4-((2S,3S,4S,5R,6R)-4,5-Bis-benzyloxy-3-bromo-2-hydroxy-6-methyl-tetrahydro-pyran-2-yl)-3-methoxy-benzoic acid 
• 132041-15-7 4-((2S,3R,4S,5R,6R)-4,5-Bis-benzyloxy-3-bromo-6-methyl-tetrahydro-pyran-2-yl)-3-methoxy-benzoic acid 
• 132040-96-1 3-Benzenesulfonyl-5-((2R,4R,5S,6R)-4,5-dihydroxy-6-methyl-tetrahydro-pyran-2-yl)-4-methoxy-3H-isobenzofuran-1-one 
• 132041-17-9 4-((2R,4R,5R,6R)-4,5-Bis-methoxymethoxy-6-methyl-tetrahydro-pyran-2-yl)-N,N-diethyl-2-formyl-3-methoxy-benzamide 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: -CH2-, - CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxyl group.]

NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

A compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof: [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.]

Synthesizing method of 4-(4-bromo-3-aldehyde-phenoxyl)-benzonitrile

The invention provides a synthesizing method of 4-(4-bromo-3-aldehyde-phenoxyl)-benzonitrile. The synthesizing method comprises the following steps of using 3-methylphenol as the starting raw material, and reacting with acid anhydride to prepare 3-methyl-benzene ester; enabling the 3-methyl-benzene ester and sulfonyl chloride to react, so as to prepare a mixture of 3-chloromethyl-benzene ester and3-dichloromethyl-benzene ester; adding ulotropine, and hydrolyzing, so as to obtain 3-hydroxyl-benzaldehyde; performing brominating reaction, so as to obtain 4-bromo-3-hydroxyl-benzaldehyde; adding 4-fluorobenzonitrile, and performing condensation reaction, so as to obtain the 4-(4-bromo-3-aldehyde-phenoxyl)-benzonitrile. The synthesizing method has the advantages that the prices of the reactionraw materials are low, the obtaining is easy, the reaction steps are fewer, the production cost is low, the technology is simple, the product purity is high and reaches 99.0% or above, and the synthesizing method is suitable for industrialized production.

Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids

We recently reported on a series of retinoid-related molecules containing an adamantyl group, a.k.a. adamantyl arotinoids (AdArs), that showed significant cancer cell growth inhibitory activity and activated RXRα (NR2B1) in transient transfection assays while devoid of RAR transactivation capacity. We have now explored whether these AdArs could also bind and inhibit IKKβ, a known target that mediates the induction of apoptosis and cancer cell growth inhibition by related AdArs containing a chalcone functional group. In addition, we have prepared and evaluated novel AdArs that incorporate a central heterocyclic ring connecting the adamantyl-phenol and the carboxylic acid at the polar termini. Our results indicate that the majority of the RXRα activating compounds lacked IKKβ inhibitory activity. In contrast, the novel heterocyclic AdArs containing a thiazole or pyrazine ring linked to a benzoic acid motif were potent inhibitors of both IKKα and IKKβ, which in most cases paralleled significant growth inhibitory and apoptosis inducing activities.

Facile p-toluenesulfonic acid-promoted para-selective monobromination and chlorination of phenol and analogues

para-Regioselective bromination of phenol and analogues, promoted by p-toluenesulfonic acid, is achieved in high to excellent yields at room temperature with N-bromosuccinimide. Chlorination with N-chlorosuccinimide and catalysed by p-toluenesulfonic acid also gives para-chlorinated phenol analogues in good yields at room temperature. para-Bromination of phenol, promoted by p-toluenesulfonic acid, is achieved in excellent yields at room temperature with N-bromosuccinimide. p-Toluenesulfonic acid is also effective as a promoter of para-chlorination with N-chlorosuccinimide.

Mild, efficient, and regioselective monobromination of arylamines and phenols using [BBIm]Br3 as a new reagent

We report here an efficient method for the synthesis and characterization of the room-temperature ionic liquid 1,3-di-n-butylimidazolium tribromide ([BBIm]Br3) (2) and its application as an efficient reagent and solvent for regioselective bromination of arylamines and phenols under mild conditions. The bromination was carried out in the absence of organic solvents, and in most cases, the only extraction solvent needed was water. The spent 1,3-di-n-butylimidazolium bromide (1) was easily recycled.

Synthesis of novel spinosyn a analogues by Pd-mediated transformations

The concept of modern crop protection demands for a continuous supply of new or modified established pesticides to avoid the development of serious resistances. Recent reports on the insecticidal spinosyns 1 and 2 show that also this class of pest managing agents is increasingly exposed to the formation of resistances. The synthesis of new derivatives is therefore highly desirable. We describe in this paper a convergent approach towards novel enantiopure spinosyn A analogues of type 3, which is based on investigations of structure-activity relationships and employs a twofold Heck reaction as key step for the preparation of the tricyclic backbone assembly.

Structure revision of medermycin/lactoquinomycin a and of related C-8 glycosylated naphthoquinones.

[reaction: see text] On the basis of chemical and spectral data, the structure of the medermycin/lactoquinomycin A has been revised, which has also led to the revision of related C-glycosylated naphthoquinone antibiotics such as lactoquinomycin B, menoxymycins A and B, G15-F, and G15-G.